Page last updated: 2024-12-09

2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide, also known as **Trifloxystrobin**, is a **fungicide** that is widely used in agriculture and horticulture.

Here's why it is important for research:

**1. Mode of Action:**

* Trifloxystrobin is a **strobilurin** fungicide, meaning it inhibits **mitochondrial respiration** in fungi by blocking the **electron transport chain** at **cytochrome bc1 complex**. This disruption prevents the fungus from producing energy and ultimately leads to its death.
* This unique mode of action makes Trifloxystrobin effective against a broad spectrum of fungal diseases, including **powdery mildew, rust, and leaf spot diseases.**

**2. Research Interest:**

* **New Disease Control:** Researchers are investigating the efficacy of Trifloxystrobin against emerging fungal diseases and developing new formulations to improve its performance.
* **Resistance Management:** Due to the widespread use of Trifloxystrobin, there is a concern about the development of fungicide resistance in fungal pathogens. Researchers are studying the mechanisms of resistance and developing strategies to manage resistance.
* **Environmental Impact:** Research is focused on the environmental fate and persistence of Trifloxystrobin, its potential impact on non-target organisms, and its contribution to soil and water contamination.
* **Synergistic Effects:** Researchers are exploring the potential for combining Trifloxystrobin with other fungicides to achieve better disease control and potentially reduce the development of resistance.
* **Novel Applications:** Researchers are investigating the potential of Trifloxystrobin in other applications, such as the control of fungal diseases in post-harvest crops and the development of new fungicides for use in forestry.

**3. Importance for Sustainable Agriculture:**

* Trifloxystrobin's effectiveness and broad spectrum of activity allow for a **reduced reliance on multiple fungicides**, leading to **lower pesticide inputs** and potentially **reduced environmental impact.**
* This contributes to **sustainable agricultural practices** and the protection of the environment.

In summary, 2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide (Trifloxystrobin) is a crucial fungicide with significant research interest due to its unique mode of action, resistance management concerns, environmental impact, and potential for novel applications. Research on Trifloxystrobin continues to play a vital role in improving disease control, ensuring food security, and promoting sustainable agricultural practices.

Cross-References

ID SourceID
PubMed CID704205
CHEMBL ID1326265
CHEBI ID92387

Synonyms (33)

Synonym
EU-0013367
MLS-0146327.0001
ml088
NCGC00100181-01
CBKINASE1_001400
CBKINASE1_013800
MLS-0146327.0002
MLS-0146327.0003 ,
MLS-0146327.0004
OPREA1_188083
2-(4-chloro-3-methylphenoxy)-n-(4h-1,2,4-triazol-3-yl)acetamide
STK151112
AKOS002953273
BRD-K21614065-001-01-8
smr001382699
MLS002460492
HMS1800C22
AKOS000643146
2-(4-chloro-3-methylphenoxy)-n-(1h-1,2,4-triazol-5-yl)acetamide
HMS2223E13
HMS3354J19
AB00110588-01
CHEMBL1326265
bdbm46436
2-(4-chloranyl-3-methyl-phenoxy)-n-(1h-1,2,4-triazol-5-yl)ethanamide
2-(4-chloro-3-methyl-phenoxy)-n-(1h-1,2,4-triazol-5-yl)acetamide
cid_704205
cambridge id 6575413
CHEBI:92387
Q27164125
429630-22-8
EN300-14816257
Z57715819
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (15)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency3.16230.631035.7641100.0000AID504339
glp-1 receptor, partialHomo sapiens (human)Potency8.91250.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency39.81070.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency23.09990.004110.890331.5287AID504466; AID504467
Microtubule-associated protein tauHomo sapiens (human)Potency15.84890.180013.557439.8107AID1460
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency3.16230.707912.194339.8107AID720542
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency42.23950.707936.904389.1251AID504333
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency15.84890.354828.065989.1251AID504847
chromobox protein homolog 1Homo sapiens (human)Potency89.71640.006026.168889.1251AID540317
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency37.93300.060110.745337.9330AID485367
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
intestinal alkaline phosphatase precursorMus musculus (house mouse)IC50 (µMol)100.00000.259011.870860.3000AID488874
alkaline phosphatase, germ cell type preproproteinHomo sapiens (human)IC50 (µMol)100.00000.110011.386267.2000AID1512
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
alkaline phosphatase, intestinalHomo sapiens (human)EC50 (µMol)15.85000.257026.839581.0000AID463120; AID488817
alkaline phosphatase, tissue-nonspecific isozyme isoform 1 preproproteinHomo sapiens (human)EC50 (µMol)28.07600.227025.090486.8000AID1659; AID488886
alkaline phosphatase, germ cell type preproproteinHomo sapiens (human)EC50 (µMol)17.00000.550033.733974.0000AID488888
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (11.11)29.6817
2010's6 (66.67)24.3611
2020's2 (22.22)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.14

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.14 (24.57)
Research Supply Index2.30 (2.92)
Research Growth Index4.44 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.14)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]